Van ECK Associates Corp Has $5.06 Million Stock Holdings in Boston Scientific Co. (NYSE:BSX)

Van ECK Associates Corp boosted its holdings in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 18.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 57,894 shares of the medical equipment provider's stock after purchasing an additional 8,882 shares during the period. Van ECK Associates Corp's holdings in Boston Scientific were worth $5,063,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. Eagle Bay Advisors LLC raised its holdings in shares of Boston Scientific by 542.1% in the first quarter. Eagle Bay Advisors LLC now owns 366 shares of the medical equipment provider's stock valued at $25,000 after buying an additional 309 shares during the last quarter. First Foundation Advisors bought a new position in shares of Boston Scientific in the first quarter worth about $25,000. Triad Wealth Partners LLC acquired a new position in shares of Boston Scientific during the second quarter worth approximately $26,000. Values First Advisors Inc. bought a new stake in shares of Boston Scientific during the third quarter valued at approximately $28,000. Finally, Andra AP fonden acquired a new stake in shares of Boston Scientific in the second quarter valued at approximately $29,000. Institutional investors own 89.07% of the company's stock.

Analyst Ratings Changes

BSX has been the topic of several research reports. Raymond James upped their price objective on Boston Scientific from $91.00 to $94.00 and gave the stock a "strong-buy" rating in a report on Wednesday, September 4th. Robert W. Baird raised their price target on Boston Scientific from $90.00 to $91.00 and gave the company an "outperform" rating in a report on Thursday, July 25th. TD Cowen boosted their price objective on Boston Scientific from $86.00 to $100.00 and gave the stock a "buy" rating in a report on Monday, October 21st. Canaccord Genuity Group raised their target price on shares of Boston Scientific from $88.00 to $98.00 and gave the company a "buy" rating in a research note on Monday, October 21st. Finally, Needham & Company LLC reissued a "hold" rating on shares of Boston Scientific in a research note on Thursday, October 31st. Four analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $93.39.

Insider Activity at Boston Scientific

In other news, EVP Wendy Carruthers sold 6,983 shares of the business's stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $81.70, for a total value of $570,511.10. Following the sale, the executive vice president now owns 37,468 shares of the company's stock, valued at $3,061,135.60. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, EVP Joseph Michael Fitzgerald sold 132,527 shares of the company's stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $85.00, for a total transaction of $11,264,795.00. Following the sale, the executive vice president now owns 160,467 shares in the company, valued at approximately $13,639,695. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Wendy Carruthers sold 6,983 shares of the firm's stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $81.70, for a total value of $570,511.10. Following the completion of the transaction, the executive vice president now owns 37,468 shares of the company's stock, valued at approximately $3,061,135.60. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 309,270 shares of company stock valued at $26,196,718. 0.50% of the stock is owned by insiders.

Boston Scientific Stock Up 1.6 %

Shares of BSX stock traded up $1.37 during trading hours on Friday, hitting $88.25. 5,242,205 shares of the company were exchanged, compared to its average volume of 7,294,248. The company has a market capitalization of $130.07 billion, a PE ratio of 72.93, a PEG ratio of 2.55 and a beta of 0.79. Boston Scientific Co. has a 52 week low of $50.84 and a 52 week high of $88.94. The business has a 50 day moving average of $84.61 and a two-hundred day moving average of $78.93. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.44.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.59 by $0.04. The firm had revenue of $4.21 billion during the quarter, compared to analysts' expectations of $4.04 billion. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. The company's revenue was up 19.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.50 EPS. Analysts anticipate that Boston Scientific Co. will post 2.46 earnings per share for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.